Literature DB >> 12086890

Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia.

Adolfo A Ferrando1, Donna S Neuberg, Jane Staunton, Mignon L Loh, Christine Huard, Susana C Raimondi, Fred G Behm, Ching Hon Pui, James R Downing, D Gary Gilliland, Eric S Lander, Todd R Golub, A Thomas Look.   

Abstract

Human T cell leukemias can arise from oncogenes activated by specific chromosomal translocations involving the T cell receptor genes. Here we show that five different T cell oncogenes (HOX11, TAL1, LYL1, LMO1, and LMO2) are often aberrantly expressed in the absence of chromosomal abnormalities. Using oligonucleotide microarrays, we identified several gene expression signatures that were indicative of leukemic arrest at specific stages of normal thymocyte development: LYL1+ signature (pro-T), HOX11+ (early cortical thymocyte), and TAL1+ (late cortical thymocyte). Hierarchical clustering analysis of gene expression signatures grouped samples according to their shared oncogenic pathways and identified HOX11L2 activation as a novel event in T cell leukemogenesis. These findings have clinical importance, since HOX11 activation is significantly associated with a favorable prognosis, while expression of TAL1, LYL1, or, surprisingly, HOX11L2 confers a much worse response to treatment. Our results illustrate the power of gene expression profiles to elucidate transformation pathways relevant to human leukemia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12086890     DOI: 10.1016/s1535-6108(02)00018-1

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  366 in total

1.  Folylpolyglutamate synthetase gene transcription is regulated by a multiprotein complex that binds the TEL-AML1 fusion in acute lymphoblastic leukemia.

Authors:  Guy J Leclerc; Christopher Sanderson; Stephen Hunger; Meenakshi Devidas; Julio C Barredo
Journal:  Leuk Res       Date:  2010-06-09       Impact factor: 3.156

2.  Transcriptional regulatory networks downstream of TAL1/SCL in T-cell acute lymphoblastic leukemia.

Authors:  Teresa Palomero; Duncan T Odom; Jennifer O'Neil; Adolfo A Ferrando; Adam Margolin; Donna S Neuberg; Stuart S Winter; Richard S Larson; Wei Li; X Shirley Liu; Richard A Young; A Thomas Look
Journal:  Blood       Date:  2006-04-18       Impact factor: 22.113

Review 3.  Molecular rearrangements and morphology in thyroid cancer.

Authors:  Todd G Kroll
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

Review 4.  International collaboration on childhood leukemia.

Authors:  Ching-Hon Pui; Raul C Ribeiro
Journal:  Int J Hematol       Date:  2003-12       Impact factor: 2.490

5.  Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization.

Authors:  Bernd B Zeisig; Tom Milne; María-Paz García-Cuéllar; Silke Schreiner; Mary-Ellen Martin; Uta Fuchs; Arndt Borkhardt; Sumit K Chanda; John Walker; Richard Soden; Jay L Hess; Robert K Slany
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

Review 6.  Beyond the 2008 World Health Organization classification: the role of the hematopathology laboratory in the diagnosis and management of acute lymphoblastic leukemia.

Authors:  Stephanie McGregor; Jennifer McNeer; Sandeep Gurbuxani
Journal:  Semin Diagn Pathol       Date:  2012-02       Impact factor: 3.464

7.  Assessing the risk of T-cell malignancies in mouse models of SCID-X1.

Authors:  Brian Sorrentino
Journal:  Mol Ther       Date:  2010-05       Impact factor: 11.454

8.  The T-ALL paradox in cancer.

Authors:  Trang Hoang; Thu Hoang
Journal:  Nat Med       Date:  2010-11       Impact factor: 53.440

9.  The TCR γδ repertoire and relative gene expression characteristics of T-ALL cases with biclonal malignant Vδ1 and Vδ2 T cells.

Authors:  Haitao Zheng; Xu Wang; Yu Ma; Bing Xu; Shaohua Chen; Lijian Yang; Xiuli Wu; Grzegorz K Przybylski; Suming Huang; Tiezhen Ye; Yangqiu Li
Journal:  DNA Cell Biol       Date:  2013-12-13       Impact factor: 3.311

Review 10.  Pediatric non-Hodgkin's lymphoma.

Authors:  Thomas G Gross; Amanda M Termuhlen
Journal:  Curr Oncol Rep       Date:  2007-11       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.